Display options
Cite
Heianza Y, Zhou T, He H, et al. Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. Int J Obes (Lond). 2021;45(12):2600-2607doi: 10.1038/s41366-021-00939-7.
Heianza, Y., Zhou, T., He, H., DiDonato, J. A., Bray, G. A., Sacks, F. M., & Qi, L. (2021). Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. International journal of obesity (2005), 45(12), 2600-2607. https://doi.org/10.1038/s41366-021-00939-7
Heianza, Yoriko, et al. "Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial." International journal of obesity (2005) vol. 45,12 (2021): 2600-2607. doi: https://doi.org/10.1038/s41366-021-00939-7
Heianza Y, Zhou T, He H, DiDonato JA, Bray GA, Sacks FM, Qi L. Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial. Int J Obes (Lond). 2021 Dec;45(12):2600-2607. doi: 10.1038/s41366-021-00939-7. Epub 2021 Aug 23. PMID: 34426648; PMCID: PMC8608703.
Copy Download .nbib Format: NLM
Share it on

Int J Obes (Lond). 2021 Dec;45(12):2600-2607. doi: 10.1038/s41366-021-00939-7. Epub 2021 Aug 23.

Changes in gut-microbiota-related metabolites and long-term improvements in lipoprotein subspecies in overweight and obese adults: the POUNDS lost trial.

International journal of obesity (2005)

Yoriko Heianza, Tao Zhou, Hua He, Joseph A DiDonato, George A Bray, Frank M Sacks, Lu Qi

Affiliations

  1. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA. [email protected].
  2. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
  3. Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, OH, USA.
  4. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.
  5. Department of Nutrition, Harvard T.H, Chan School of Public Health, Boston, MA, USA.
  6. Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA. [email protected].
  7. Department of Nutrition, Harvard T.H, Chan School of Public Health, Boston, MA, USA. [email protected].

PMID: 34426648 PMCID: PMC8608703 DOI: 10.1038/s41366-021-00939-7

Abstract

BACKGROUND/OBJECTIVES: Alterations in gut microbiota have been linked to obesity and impaired lipid metabolism. Lipoproteins are heterogeneous, and lipoprotein subspecies containing apolipoprotein C-III (apoCIII) have adverse associations with obesity and related cardiometabolic abnormalities. We investigated associations of weight-loss diet-induced decreases in atherogenic gut-microbial metabolites, trimethylamine N-oxide (TMAO) and L-carnitine, with improvements in atherogenic lipoproteins containing apoCIII among patients with obesity.

SUBJECTS/METHODS: This study included overweight and obese adults who participated in a 2-year weight-loss dietary intervention, the POUNDS Lost trial. Blood levels of TMAO and L-carnitine were measured at baseline and 6 months after the intervention; 6-month changes in the metabolites were calculated. We evaluated 2-year changes in lipid profiles (n = 395) and cholesterol [Chol] in lipoprotein (very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) subfractions defined by the presence or absence of apoCIII (n = 277).

RESULTS: The initial (6-month) decrease in L-carnitine was significantly associated with long-term (2-year) reductions in non-HDL-Chol and LDL-Chol (p < 0.05). Also, the decrease in L-carnitine was significantly related to decreases in Chol in LDL with apoCIII (p = 0.034) and Chol in [LDL + VLDL] with apoCIII (p = 0.018). We found significant interactions between dietary fat and TMAO on changes in LDL-Chol (P

CONCLUSIONS: Changes in TMAO and L-carnitine induced by weight-loss diets were associated with long-term improvements in atherogenic lipoproteins containing apoCIII, implicating that these metabolic changes might be predictive of an individual's response to the dietary treatment to modify the unfavorable lipid profiles in obese patients. Dietary fat intake might modify associations of TMAO changes with long-term improvements of atherogenic cholesterol metabolism in overweight and obese adults. CLINICALTRIALS.

GOV IDENTIFIER: NCT00072995.

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

References

  1. Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):169-183 - PubMed
  2. J Clin Invest. 2019 Jan 2;129(1):373-387 - PubMed
  3. J Am Coll Cardiol. 2017 Feb 21;69(7):789-800 - PubMed
  4. Am J Clin Nutr. 2016 Mar;103(3):703-11 - PubMed
  5. Nutr Metab Cardiovasc Dis. 2019 May;29(5):513-517 - PubMed
  6. Semin Liver Dis. 2013 Nov;33(4):343-57 - PubMed
  7. Diabetes Care. 2018 Mar;41(3):413-419 - PubMed
  8. J Clin Lipidol. 2015 Nov-Dec;9(6):733-740 - PubMed
  9. Cell Metab. 2013 Jan 8;17(1):49-60 - PubMed
  10. J Lipid Res. 2015 Jan;56(1):22-37 - PubMed
  11. Nat Med. 2013 May;19(5):576-85 - PubMed
  12. Eur Heart J. 2020 Jun 21;41(24):2313-2330 - PubMed
  13. Clin Nutr. 2019 Dec;38(6):2504-2520 - PubMed
  14. Cell Host Microbe. 2018 Apr 11;23(4):458-469.e5 - PubMed
  15. Am J Clin Nutr. 2020 Jun 1;111(6):1226-1234 - PubMed
  16. Nat Commun. 2015 Apr 07;6:6498 - PubMed
  17. J Am Coll Cardiol. 2020 Feb 25;75(7):763-772 - PubMed
  18. J Lipid Res. 2007 May;48(5):1190-203 - PubMed
  19. N Engl J Med. 2011 Oct 27;365(17):1597-604 - PubMed
  20. J Clin Endocrinol Metab. 2008 Feb;93(2):557-64 - PubMed
  21. Curr Opin Lipidol. 2015 Feb;26(1):56-63 - PubMed
  22. J Clin Lipidol. 2017 Jan - Feb;11(1):224-233.e2 - PubMed
  23. Nat Commun. 2019 Dec 20;10(1):5813 - PubMed
  24. Curr Opin Endocrinol Diabetes Obes. 2015 Apr;22(2):119-25 - PubMed
  25. Nat Med. 2017 Jul;23(7):859-868 - PubMed
  26. Cell Rep. 2018 Jul 24;24(4):935-946 - PubMed
  27. Circulation. 2018 Mar 27;137(13):1364-1373 - PubMed
  28. Circulation. 2010 Apr 20;121(15):1722-34 - PubMed
  29. Nat Rev Microbiol. 2018 Mar;16(3):171-181 - PubMed
  30. Sci Rep. 2016 May 27;6:26745 - PubMed
  31. Curr Opin Lipidol. 2015 Oct;26(5):426-31 - PubMed
  32. J Am Heart Assoc. 2017 Jun 29;6(7): - PubMed
  33. N Engl J Med. 2009 Feb 26;360(9):859-73 - PubMed
  34. Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):853-8 - PubMed
  35. J Clin Lipidol. 2015 Jul-Aug;9(4):498-510 - PubMed
  36. Diabetes Metab. 2021 Mar;47(2):101183 - PubMed
  37. Environ Health. 2020 Jan 13;19(1):5 - PubMed
  38. Nature. 2011 Apr 7;472(7341):57-63 - PubMed
  39. Circulation. 2011 Nov 8;124(19):2065-72 - PubMed
  40. Circ Res. 2019 Jun 7;124(12):1808-1820 - PubMed
  41. Int J Food Sci Nutr. 2017 Jun;68(4):488-495 - PubMed
  42. Obesity (Silver Spring). 2015 Dec;23(12):2357-63 - PubMed
  43. Gut. 2019 Feb;68(2):263-270 - PubMed
  44. Sci Rep. 2016 Jan 08;6:19076 - PubMed
  45. Rev Endocr Metab Disord. 2019 Dec;20(4):461-472 - PubMed
  46. Clin Chem Lab Med. 2017 Feb 1;55(2):261-268 - PubMed
  47. Nat Med. 2018 Sep;24(9):1407-1417 - PubMed
  48. Cell Rep. 2015 Jan 20;10(3):326-338 - PubMed
  49. J Lipid Res. 2014 Oct;55(10):2167-77 - PubMed
  50. N Engl J Med. 2013 Apr 25;368(17):1575-84 - PubMed
  51. Nutr Res. 2015 Oct;35(10):858-864 - PubMed

Publication Types

Grant support